680 filings
Page 11 of 34
8-K
sv5hn6ok
6 Mar 17
Dynavax Presents Promising Clinical Data from Lead Immuno-Oncology Candidate, SD-101, at the International Congress on Targeted Anticancer Therapies
12:00am
8-K
3xc30g 61r
28 Feb 17
Dynavax Announces FDA Acceptance for Review of its Complete Response to November 2016 CRL
12:00am
POSASR
hn4t fxs76mg0s1mej8
14 Feb 17
Automatic shelf registration (post-effective amendment)
12:00am
8-K/A
5s4l7p71zuf36f3p
13 Jan 17
Cost Associated with Exit or Disposal Activities
12:00am
8-K
6vztj8z
5 Jan 17
Results of Operations and Financial Condition
12:00am
8-K
vf03q
23 Dec 16
Termination of a Material Definitive Agreement
12:00am
8-K
2tm8bp 5tpk0ew
5 Dec 16
Dynavax Presents Clinical Data from
12:00am
8-K
2b0f6ab2qdzlwq8i
14 Nov 16
Dynavax Receives Complete Response Letter from U.S. Food and Drug Administration
12:00am
8-K
w2atav2rgolhpc8qo9si
9 Nov 16
Dynavax Presents Early Clinical Data from Lead Cancer Immunotherapy Candidate, SD-101, at Society for Melanoma Research
12:00am
CT ORDER
gq14r2s5humo 2bkuzs
8 Nov 16
Confidential treatment order
12:00am
CT ORDER
b4roz 5bi
8 Nov 16
Confidential treatment order
12:00am
CT ORDER
d5oszo 2en2r251r8h
8 Nov 16
Confidential treatment order
12:00am
CT ORDER
zy2od rrcv0h5
8 Nov 16
Confidential treatment order
12:00am
CT ORDER
blm6a89
8 Nov 16
Confidential treatment order
12:00am
8-K
zf1lbtxho 7hf
7 Nov 16
Results of Operations and Financial Condition
12:00am
8-K
adcx76840kstfk7
27 Oct 16
Entry into a Material Definitive Agreement
12:00am
8-K
o7ulci c4ojpq5
11 Oct 16
Dynavax Presents Early Clinical Data from Lead Cancer Immunotherapy Candidate, SD-101, at ESMO Annual Congress
12:00am
8-K
xlgnhgip 5s9e
3 Oct 16
Other Events
12:00am
8-K
ce2f7cj d2s
6 Sep 16
Dynavax Provides regulatory update on HEPLISAV-B
12:00am